1-1 of 1
Nikola Goekbuget, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD
Journal: Blood
Blood (2008) 112 (11): 1926.
https://doi.org/10.1182/blood.V112.11.1926.1926
Published: 2008